Consistently, upregulation of CSNK2A1 expression has been observed in various cancer types, including the colorectal cancer [33], stomach cancer [34], head and neck cancer [35], kidney cancer [36, 37], and prostate cancer [38], compared to noncancerous tissues. This evidence concerns the gene CSNK2A1 and head and neck cancer.